The DOI matches its Crossref record.
Cancer Immunotherapy
Abstract
This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that CRISPR-Cas9 has been applied in T cell modification 70 and immune modulation, 70 71”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [70]
Citations
Cited by
Sorted by citations
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
“…analysis at multiple target sites could be a high-throughput solution for understanding binding degeneracy (Wu et al., 2014), whereas techniques for detecting and labeling double-strand breaks (Crosetto et al., 2013) will help to achieve a comprehensive map of Cas9-induced off-target indels.”
BackgroundDelivery technologies for cancer immunotherapy
Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,678
30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology
Zhang, Q., Lenardo, M. J., & Baltimore, D. (2017) · Cell · doi:10.1016/j.cell.2016.12.012 · Cited by 1,979
“Finally, as the pivotal role of the immune system in fighting malignancy has come into focus with new discoveries in immunotherapy, NF-κB inhibition is cast into a new light (Couzin-Frankel, 2013).”
Challenges in liver cancer and possible treatment approaches
Anwanwan, D., Singh, S. K., Singh, S., Saikam, V., & Singh, R. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188314 · Cited by 1,491
Garrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
Metadata
- Authors
- Couzin-Frankel, J.
- Corresponding author
- Couzin-Frankel, Jennifer
- Venue
- Science
- Published
- 2013-12-20
- Volume
- 342
- Issue
- 6165
- Pages
- 1432-1433
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2209812019
- Cited by
- 2,051
- References
- 0
- Citations by year
- 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
- FWCI
- 73.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
- MeSH terms
- Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
